DH Yates, HS Sussman, MJ Shaw, PJ Barnes and KF Chung
Department of Thoracic Medicine, National Heart & Lung Institute, London, United Kingdom.

Regular beta 2-adrenoceptor agonist therapy may lead to a rebound increase in bronchial responsiveness on discontinuation of therapy and a reduction in bronchoprotective effects. Formoterol, a long-acting beta 2-agonist, is effective in single doses in the prevention of methacholine-induced bronchoconstriction. In a double-blind, placebo- controlled cross-over study, we examined the effect of an inhaled long- acting beta 2-adrenoceptor agonist, formoterol (24 micrograms twice a day) for 2 wk on airway function and responsiveness in 17 subjects with mild asthma (mean age, 26.3 +/- 1.4 yr) who were not taking inhaled glucocorticosteroids. FEV1 and the provocative concentration of methacholine causing a 20% fall in FEV1 (PC20) were measured at 36, 60, and 108 h and at 2 wk after the last dose of regular treatment. In addition, PC20 was measured 12 h after the first and the last dose of formoterol and placebo. PC20 values at 36, 60, and 108 h and at 2 wk after formoterol treatment cessation were not significantly different from those after placebo. Mean FEV1 was 3.44 +/- 0.18 L after placebo compared with 3.79 +/- 0.20 L after formoterol (p < 0.001) 12 h after the first dose, and mean PC20 was 0.53 (GSEM 1.4) mg/ml after placebo compared with 2.0 (GSEM 1.4) mg/ml after formoterol (p < 0.001). After 2 wk of regular treatment, mean FEV1 at 12 h after the final dose of formoterol fell to 3.51 +/- 0.23 L compared with 3.41 +/- 0.18 L after the final dose of placebo (p = 0.03).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				P. J. Barnes Scientific rationale for using a single inhaler for asthma control Eur. Respir. J., March 1, 2007; 29(3): 587 - 595. [Abstract] [Full Text] [PDF]

				J. A. van Noord, J. L. Aumann, E. Janssens, J. Verhaert, J. J. Smeets, A. Mueller, and P. J. G. Cornelissen Effects of Tiotropium With and Without Formoterol on Airflow Obstruction and Resting Hyperinflation in Patients With COPD Chest, March 1, 2006; 129(3): 509 - 517. [Abstract] [Full Text] [PDF]

				J. A. van Noord, J-L. Aumann, E. Janssens, J. J. Smeets, J. Verhaert, B. Disse, A. Mueller, and P. J. G. Cornelissen Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD Eur. Respir. J., August 1, 2005; 26(2): 214 - 222. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter Cardiovascular Effects of {beta}-Agonists in Patients With Asthma and COPD: A Meta-Analysis Chest, June 1, 2004; 125(6): 2309 - 2321. [Abstract] [Full Text] [PDF]

				S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter Meta-Analysis: Respiratory Tolerance to Regular {beta}2-Agonist Use in Patients with Asthma Ann Intern Med, May 18, 2004; 140(10): 802 - 813. [Abstract] [Full Text] [PDF]

				M. Wadbo, C-G. Lofdahl, K. Larsson, B.E. Skoogh, G. Tornling, E. Arwestrom, T. Bengtsson, and K. Strom Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study Eur. Respir. J., November 1, 2002; 20(5): 1138 - 1146. [Abstract] [Full Text] [PDF]

				J. C. KIPS and R. A. PAUWELS Long-acting Inhaled beta 2-Agonist Therapy in Asthma Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932. [Full Text] [PDF]

				H J van der Woude, T H Winter, and R Aalbers Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting {beta}2 agonists Thorax, July 1, 2001; 56(7): 529 - 535. [Abstract] [Full Text] [PDF]

				S. G. M. Cloosterman, I. D. Bijl-Hofland, C. L. A. van Herwaarden, R. P. Akkermans, F. J. J. van den Elshout, H. T. M. Folgering, and C. P. van Schayck A Placebo-Controlled Clinical Trial of Regular Monotherapy With Short-Acting and Long-Acting {beta}2-Agonists in Allergic Asthmatic Patients Chest, May 1, 2001; 119(5): 1306 - 1315. [Abstract] [Full Text] [PDF]

				{beta}2-Agonists Can. Med. Assoc. J., November 1, 1999; 161(90111): s28 - 31. [Full Text]

				M. PALMQVIST, T. IBSEN, A. MELLÉN, and J. LÖTVALL Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 244 - 249. [Abstract] [Full Text]

				I. Aziz and B. J. Lipworth A Bolus of Inhaled Budesonide Rapidly Reverses Airway Subsensitivity and {beta}2-Adrenoceptor Down-regulation After Regular Inhaled Formoterol Chest, March 1, 1999; 115(3): 623 - 628. [Abstract] [Full Text] [PDF]

				J A van Noord, A J M Schreurs, S J M Mol, and P G H Mulder Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma Thorax, March 1, 1999; 54(3): 207 - 212. [Abstract] [Full Text]

				P. J. BARNES Pharmacology of Airway Smooth Muscle Am. J. Respir. Crit. Care Med., November 1, 1998; 158(2007): S123 - S132. [Abstract] [Full Text] [PDF]

				M. JOHNSON The beta -Adrenoceptor Am. J. Respir. Crit. Care Med., November 1, 1998; 158(2007): S146 - S153. [Abstract] [Full Text] [PDF]

				R. A. Pauwels, C.-G. Lofdahl, D. S. Postma, A. E. Tattersfield, P. O'Byrne, P. J. Barnes, A. Ullman, and The Formoterol and Corticosteroids Establishing Th Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma N. Engl. J. Med., November 13, 1997; 337(20): 1405 - 1411. [Abstract] [Full Text] [PDF]

				D. H. YATES, M. WORSDELL, and P. J. BARNES Effect of Regular Salmeterol Treatment on Albuterol-induced Bronchoprotection in Mild Asthma Am. J. Respir. Crit. Care Med., September 1, 1997; 156(3): 988 - 991. [Abstract] [Full Text] [PDF]

				K. S. TAN, A. GROVE, A. M. LEAN, Y. GNOSSPELIUS, I. P. HALL, and B. J. LIPWORTH Systemic Corticosteriod Rapidly Reverses Bronchodilator Subsensitivity Induced by Formoterol in Asthmatic Patients Am. J. Respir. Crit. Care Med., July 1, 1997; 156(1): 28 - 35. [Abstract] [Full Text]